Barclays PLC Raises Stake in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Barclays PLC lifted its stake in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 8.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,881 shares of the company’s stock after purchasing an additional 2,575 shares during the quarter. Barclays PLC owned about 0.05% of Pulse Biosciences worth $573,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. purchased a new stake in shares of Pulse Biosciences in the fourth quarter worth $311,000. Vanguard Group Inc. raised its holdings in Pulse Biosciences by 15.1% in the 4th quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company’s stock worth $19,958,000 after acquiring an additional 150,506 shares during the last quarter. Norges Bank purchased a new position in Pulse Biosciences in the 4th quarter worth approximately $348,000. Legal & General Group Plc increased its holdings in shares of Pulse Biosciences by 23.8% in the 4th quarter. Legal & General Group Plc now owns 18,303 shares of the company’s stock worth $319,000 after purchasing an additional 3,521 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Pulse Biosciences by 1,956.7% in the fourth quarter. Invesco Ltd. now owns 214,490 shares of the company’s stock worth $3,734,000 after purchasing an additional 204,061 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Price Performance

Shares of NASDAQ:PLSE opened at $16.85 on Friday. Pulse Biosciences, Inc. has a 52-week low of $6.66 and a 52-week high of $25.00. The stock’s 50-day simple moving average is $16.66 and its two-hundred day simple moving average is $18.01.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Thursday, May 8th. The company reported ($0.25) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Monday, March 31st.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.